Skip to contentX
Xenon Pharmaceuticals Inc.
X
XENEXenon Pharmaceuticals Inc. Q3 2016 · 10-Q
Revenue$413.00K$413.00K−90.4% vs Q3 2015 Net Income-$7.71M-$7.71MN/M vs Q3 2015 EPS Diluted-$0.51-$0.51N/M vs Q3 2015 Operating Income-$7,331,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Xenon Pharmaceuticals Inc. · CIK 1582313 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$4,570,000N/M Margins · derivedOperating margin-1775.1%−1756.0 pt vs Q3 2015
Net margin-1867.8%−1778.7 pt vs Q3 2015
ended Sep 30, 2016 · filed Nov 3, 2016 · 34 d after period end